February 14, 2017, New York, NY – The Food and Drug Administration (FDA) has named Suzanne Robotti, founder and president of MedShadow Foundation, to its Drug Safety and Risk Management Advisory Committee as the Consumer Representative. Next month, she will attend her first hearing where a prescription opioid drug will Continue Reading →
June 13, 2016, New York, NY – MedShadow has been recognized with a Spring 2016 Digital Health Awards Silver designation for its website in the Nonprofit category. Winners were announced on June 10th. Formerly known as the Web Health Awards, the Digital Health Awards are held twice each year – Continue Reading →
“There’s a straight line between the overprescribing of opioids, the public’s misconceptions about these drugs and the rapidly rising number of accidental deaths from opioid addiction.”
Online health advocacy source broadens coverage of side effects, risks and benefits of medicine
NEW YORK, NY, April 28th, 2016 – MedShadow Foundation, an online nonprofit that educates consumers on the side effects, risks and benefits of medicine, has announced the appointment of Jonathan Block as Content Editor.
“We Continue Reading →
More Press Releases →
Polypharmacy–the prescribing of multiple medications simultaneously–is a big problem, especially among seniors. Surveys reveal that the average 65+ individual takes 14 prescription medications per year! It’s not uncommon to see elderly patients taking 6 or 7 drugs daily. Su Robotti, founder of the Medshadow Foundation (www.medshadow.org), highlights the dangers of excessive medication. Part 1 here; Part 2 here.
It is estimated that more than 50 million Americans have arthritis, which is the top cause of disability in the United States. The disease affects women and older adults more often than men and younger folks, though people of all sexes, ages and races can have it. There are quite Continue Reading →
Featured as part of The Story Exchange’s 1000+ Stories campaign dedicated to telling the personal and professional stories of women business owners — and to exploring the role of entrepreneurship in advancing women’s economic independence. Read Suzanne Robotti’s story here.
A panel of US Food and Drug Administration (FDA) experts has advised the agency that the risks of an abuse-deterrent extended-release formulation of oxymorphone (Opana ER, Endo Pharmaceuticals) for relief of severe pain now outweigh its benefits. Read here.